Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLP-1 Treatment for Obesity and Mental Health
NCT07368855Completed
- Sponsor
- University of California, San Diego
- Start
- May 2024
- Primary completion
- Jul 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of semaglutide and tirzepatide in obesity, major depressive disorder (MDD) and eating disorder, sponsored by University of California, San Diego. Primary endpoint: Beck Depression Inventory-2 at 6 months. Started May 2024; status: completed.
02
Drugs
03
Conditions
obesitymajor depressive disorder (MDD)eating disorder
Beyond the preview
Go deeper on NCT07368855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07368855.